Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, is preparing to file its quarterly financials. The company, founded in 2020, has built a significant asset portfolio while maintaining expenditures below $40 million. CEO Ryan Saadi emphasized the importance of balancing growth with shareholder value preservation, particularly noting the potential equity dilution from warrant conversion at $11.50 per share. The company is currently developing plans for R&D and manufacturing facilities while focusing on sustainable business practices.
Tevogen Bio (Nasdaq: TVGN), una biotech specializzata in immunoterapia in fase clinica, si sta preparando a presentare i suoi risultati finanziari trimestrali. Fondata nel 2020, l'azienda ha creato un portafoglio di asset significativo, mantenendo però le spese sotto 40 milioni di dollari. Il CEO Ryan Saadi ha sottolineato l'importanza di bilanciare la crescita con la preservazione del valore per gli azionisti, rilevando in particolare il potenziale di diluizione del capitale derivante dalla conversione delle opzioni a 11,50 dollari per azione. Attualmente, l'azienda sta sviluppando piani per impianti di ricerca e sviluppo e per la produzione, concentrandosi su pratiche commerciali sostenibili.
Tevogen Bio (Nasdaq: TVGN), una biotecnológica especializada en inmunoterapia en etapa clínica, se está preparando para presentar sus resultados financieros trimestrales. Fundada en 2020, la empresa ha construido un portafolio de activos significativo mientras mantiene los gastos por debajo de 40 millones de dólares. El CEO Ryan Saadi enfatizó la importancia de equilibrar el crecimiento con la preservación del valor para los accionistas, señalando especialmente la posible dilución de capital debido a la conversión de warrants a 11,50 dólares por acción. Actualmente, la empresa está desarrollando planes para instalaciones de I+D y manufactura, mientras se enfoca en prácticas comerciales sostenibles.
Tevogen Bio (Nasdaq: TVGN), 임상 단계의 전문 면역 요법 생명공학 회사,가 분기 재무 보고서를 제출할 준비를 하고 있습니다. 2020년에 설립된 이 회사는 4000만 달러 이하로 지출을 유지하면서 상당한 자산 포트폴리오를 구축했습니다. CEO 라이언 사아디는 주주 가치를 유지하는 것과 성장을 균형 있게 보존하는 것의 중요성을 강조하며, 주당 11.50달러에서의 워런트 전환으로 인한 잠재적인 자본 희석을 특히 언급했습니다. 현재 회사는 연구 개발 및 제조 시설 계획을 개발하는 동시에 지속 가능한 비즈니스 관행에 집중하고 있습니다.
Tevogen Bio (Nasdaq: TVGN), une biotech spécialisée en immunothérapie en phase clinique, se prépare à déposer ses résultats financiers trimestriels. Fondée en 2020, l'entreprise a constitué un portefeuille d'actifs significatif tout en maintenant ses dépenses en dessous de 40 millions de dollars. Le PDG Ryan Saadi a souligné l'importance de trouver un équilibre entre la croissance et la préservation de la valeur pour les actionnaires, notant en particulier la dilution potentielle des capitaux résultant de la conversion des bons de souscription à 11,50 dollars par action. L'entreprise développe actuellement des plans pour des installations de recherche et développement ainsi que de production, tout en se concentrant sur des pratiques commerciales durables.
Tevogen Bio (Nasdaq: TVGN), ein biotechnologisches Unternehmen für spezialisierte Immuntherapie in der klinischen Phase, bereitet sich darauf vor, seine vierteljährlichen Finanzberichte einzureichen. Das 2020 gegründete Unternehmen hat ein bedeutendes Portfolio an Vermögenswerten geschaffen und dabei die Ausgaben unter 40 Millionen Dollar gehalten. CEO Ryan Saadi betonte die Wichtigkeit der Balance zwischen Wachstum und der Erhaltung des Aktionärswertes, insbesondere im Hinblick auf die mögliche Kapitalverwässerung durch die Umwandlung von Warrants bei 11,50 Dollar pro Aktie. Das Unternehmen entwickelt derzeit Pläne für Forschungs- und Entwicklungs- sowie Produktionsstätten und konzentriert sich auf nachhaltige Geschäftspraktiken.
- Maintained low expenditures under $40 million since 2020, significantly below industry standards
- Development of significant asset portfolio
- Progress on R&D and manufacturing facility plans
- Potential shareholder dilution from warrant conversion at $11.50 per share
- Need for additional capital to fuel growth
Insights
The financial update reveals a notably lean operational model, with total expenditures of
The emphasis on avoiding equity dilution while pursuing growth indicates management's shareholder-centric approach, though the lack of concrete financial metrics and reliance on qualitative statements makes it difficult to fully assess the company's financial health. Investors should watch for the upcoming quarterly financials for a more complete picture of the company's financial position.
Key Takeaways:
- Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under
$40 million , a fraction of the industry norm. - Tevogen’s success would not be possible without its passionate team united by a common vision.
- Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution.
- Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of
$11.50 per share.
WARREN, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it is preparing to file its quarterly financials. Reflecting on the company’s progress, Founder and CEO Ryan Saadi shared insights into Tevogen Bio's unique approach to building an innovative biotech company with a disciplined and sustainable business model.
In his conversation with the leadership team, Dr. Saadi shared, “Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under
Dr. Saadi continued, “Transient quick wins or impressive numbers may give the illusion of success, but true success is sustainable and cannot be achieved without bringing everyone on the journey — be it a company or an entire society. Aim to create a lasting impact that leaves no one behind; success will follow.”
In conclusion, Dr. Saadi said, “Patience has never been my strongest suit. With the first architectural renderings for the R&D and manufacturing site underway, I know my team won’t fail to impress me yet again. But no matter how fast it all comes together, it will always feel too late - as long as those heartbreaking pleas from fellow human beings fill my inbox, reminding me of my deepest calling. Thank you, Team Tevogen.”
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is Tevogen Bio's (TVGN) total expenditure since 2020?
What is the warrant conversion strike price for Tevogen Bio (TVGN) shares?
What are Tevogen Bio's (TVGN) current development plans?
